Sage Therapeutics, Inc.Sage Therapeutics, Inc.Sage Therapeutics, Inc.

Sage Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪928.05 M‬USD
−9.05USD
‪−541.49 M‬USD
‪86.46 M‬USD
‪49.05 M‬
Beta (1Y)
1.81

About Sage Therapeutics, Inc.

CEO
Barry E. Greene
Headquarters
Cambridge
Website
Employees (FY)
487
Founded
2010
ISIN
US78667J1088
FIGI
BBG0025X16Y5
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of SAGE is 15.32 USD — it has decreased by 0.78% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sage Therapeutics, Inc. stocks are traded under the ticker SAGE.
Sage Therapeutics, Inc. is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Sage Therapeutics, Inc. has a max estimate of 70.00 USD and a min estimate of 20.00 USD.
SAGE earnings for the last quarter are −3.37 USD whereas the estimation was −2.68 USD which accounts for −25.60% surprise. Estimated earnings for the next quarter are −1.28 USD. See more details about Sage Therapeutics, Inc. earnings.
Sage Therapeutics, Inc. revenue for the last quarter amounts to ‪2.72 M‬ USD despite the estimated figure of ‪4.63 M‬ USD. In the next quarter revenue is expected to reach ‪61.03 M‬ USD.
Yes, you can track Sage Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, SAGE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sage Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
SAGE reached its all-time high on Jan 31, 2018 with the price of 195.97 USD, and its all-time low was 15.28 USD and was reached on Apr 12, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 487.00 employees. See our rating of the largest employees — is Sage Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sage Therapeutics, Inc. EBITDA is ‪−545.07 M‬ USD, and current EBITDA margin is −630.47%. See more stats in Sage Therapeutics, Inc. financial statements.